Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05654506 · ClinicalTrials.gov registry record · Phase 2
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
A Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT05654506: Recruiting Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits, sponsored by Mayo Clinic.
NCT05654506 is a Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05654506, a Phase 2 study of Proliferative Glomerulonephritis With Monoclonal IgG Deposits, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Primary Outcome
Change in protein in the urine from baseline to 12 months of follow-up
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (4)
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University North Carolina at Chapel Hill - Chapel Hill
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT05654506 shows while recruiting
NCT05654506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Proliferative Glomerulonephritis With Monoclonal IgG Deposits appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT05654506 reports a single indexed study location in Florida, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05654506 about?
NCT05654506 is a clinical study titled "Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits". The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
What is the current status of trial NCT05654506?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-08-17. Estimated completion is 2026-08.
What conditions does trial NCT05654506 study?
This clinical trial studies the following conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits.
What interventions are being tested in trial NCT05654506?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT05654506?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05654506 being conducted?
This trial has 4 study locations across Florida, Minnesota, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05654506's enrollment target sits among peer trials
40 1362nd of 2000 higher than 543 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI